Pyroptosis is a highly inflammatory form of programmed cell death mediated by gasdermin pores, driven by inflammasome activation. In Progressive Supranuclear Palsy (PSP), mounting evidence demonstrates that the NLRP3 inflammasome pathway plays a significant role in propagating neuroinflammation, driving neuronal loss, and accelerating disease progression. Unlike apoptosis, pyroptosis releases intracellular inflammatory contents, including IL-1β, IL-18, and alarmins, creating a self-perpetuating inflammatory cascade that correlates with the characteristic tau pathology burden in PSP-affected brain regions.
This mechanism represents a critical gap in understanding PSP pathogenesis, as it bridges innate immune activation with irreversible cell death in regions particularly vulnerable to 4R-tau aggregation, including the basal ganglia, brainstem nuclei, and subcortical white matter.
¶ Structure and Activation
The NLRP3 (NLR family pyrin domain containing 3) inflammasome is a multi-protein complex that initiates the inflammatory cascade:
- Sensor protein: NLRP3 detects pathogen-associated molecular patterns (PAMPs), damage-associated molecular patterns (DAMPs), and intracellular stress signals
- Adaptor protein: ASC (PYCARD) bridges NLRP3 to pro-caspase-1
- Effector protease: Caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms
In PSP, NLRP3 inflammasome activation occurs through multiple converging pathways:
- Tau aggregate recognition: Pathological tau assemblies serve as DAMPs that activate NLRP3
- Mitochondrial dysfunction: Complex I deficiency and ROS generation trigger inflammasome assembly
- Lysosomal rupture: Cathepsin B release from damaged lysosomes activates NLRP3
- ATP signaling: Extracellular ATP via P2X7 receptors promotes inflammasome formation
Postmortem studies demonstrate NLRP3 inflammasome activation in PSP brains:
- NLRP3 expression: Elevated NLRP3 protein levels in the globus pallidus, subthalamic nucleus, and substantia nigra
- ASC speck formation: Pyroptotic ASC specks detected in microglia surrounding tau-positive neurons
- Caspase-1 activation: Active caspase-1 localized to affected regions, co-localizing with 4R-tau inclusions
- Proximity ligation assays: Direct interaction between NLRP3 and ASC adaptors demonstrated in PSP tissue
| Brain Region |
NLRP3 Activation |
Correlation with Tau Burden |
| Globus pallidus (internus) |
Very high |
Strong positive |
| Subthalamic nucleus |
High |
Strong positive |
| Substantia nigra (pars reticulata) |
High |
Moderate |
| Red nucleus |
Moderate-High |
Moderate |
| Brainstem raphe nuclei |
Moderate |
Moderate |
| Frontal cortex |
Low-Moderate |
Weak |
¶ Gasdermin D and Pyroptotic Cell Death
Gasdermin D (GSDMD) is the key executioner of pyroptosis:
- Caspase-1 cleavage: Active caspase-1 cleaves GSDMD at Asp275
- N-terminal fragment: The GSDMD-NT fragment oligomerizes and inserts into the plasma membrane
- Pore formation: 10-20nm pores form, disrupting membrane integrity
- Cell swelling: Water influx causes characteristic cell swelling
- Inflammatory release: IL-1β, IL-18, alarmins, and cellular contents are released
- GSDMD cleavage: Elevated levels of cleaved GSDMD in PSP brain tissue
- GSDMD-NT localization: Active GSDMD-NT fragment detected in neurons and microglia
- Neuronal vulnerability: Pyroptotic neurons show tau pathology burden
- Microglial pyroptosis: Active microglial pyroptosis contributes to chronic inflammation
| Cell Type |
Pyroptosis Markers |
Contribution to PSP |
| Neurons |
Cleaved GSDMD, active caspase-1 |
Direct neuronal loss in vulnerable regions |
| Microglia |
ASC specks, NLRP3, IL-1β release |
Propagation of neuroinflammation |
| Astrocytes |
GSDMD activation (less prominent) |
Reactive astrogliosis contribution |
| Oligodendrocytes |
Limited evidence |
Myelin degeneration role |
¶ CSF and Blood Biomarker Evidence
Elevated inflammasome-related proteins in PSP CSF provide peripheral evidence of central activation:
- IL-1β: Elevated in PSP vs. controls (mean 45.2 pg/mL vs. 18.3 pg/mL)
- IL-18: Significantly elevated in PSP, distinguishing from PD
- ASC: Detectable ASC specks in PSP CSF at higher levels than AD or controls
- Caspase-1: Active caspase-1 measurable in PSP CSF
- Plasma GSDMD: Elevated cleaved GSDMD in PSP patients
- Extracellular vesicles: Inflammasome-derived EVs carrying NLRP3, ASC, and caspase-1 detected in plasma
- Cytokine signature: Combined IL-1β + IL-18 + IL-6 signature shows diagnostic potential
| Biomarker |
PSP |
CBD |
AD |
PD |
| CSF IL-1β |
++ |
+ |
+++ |
+ |
| CSF IL-18 |
+++ |
++ |
++ |
+ |
| Plasma GSDMD |
++ |
+ |
+ |
- |
| ASC specks |
++ |
+ |
+++ |
- |
- Pathological tau aggregates activate NLRP3 through physical interaction
- Tau fibrils as DAMPs: pattern recognition receptor engagement
- Post-translational modifications on tau: phosphorylation state affects inflammasome activation
- Tau accumulation in lysosomes disrupts membrane integrity
- Cathepsin B release activates NLRP3
- Autophagy impairment prevents removal of damaged components
- Tau-induced mitochondrial dysfunction generates ROS
- Mitochondrial DNA (mtDNA) released into cytosol activates NLRP3
- ATP depletion impairs cellular energetics, promoting inflammatory responses
- Initial tau pathology triggers NLRP3 activation
- IL-1β and IL-18 release cause neuronal stress
- Stressed neurons release additional DAMPs
- Microglial and astrocytic inflammasomes become activated
- Chronic inflammation drives further tau pathology
- Positive feedback loop accelerates disease progression
The inflammasome signature shows promise for:
- Differential diagnosis: PSP vs. PD and MSA
- Disease progression marker: Correlation with clinical deterioration
- Therapeutic monitoring: Target engagement for inflammasome inhibitors
- MCC950: Potent NLRP3 inhibitor showing efficacy in preclinical PSP models
- Dapansutrile: Oral NLRP3 inhibitor in clinical trials for neurodegenerative diseases
- Natural compounds: Quercetin, curcumin show NLRP3-modulatory activity
- IL-1β targeting: Canakinumab (anti-IL-1β) consideration in PSP
- IL-18 targeting: Anti-IL-18 therapies under investigation
- Gasdermin inhibition: GSDMD inhibitors in development
- NLRP3 inhibition combined with tau-targeted therapies
- Anti-inflammatory + anti-aggregation combination strategies
- Neuroprotective approaches alongside inflammasome modulation
Recent single-cell transcriptomics studies have illuminated cell-type-specific inflammasome activation in PSP:
- Microglial NLRP3 signatures: Single-nucleus RNA-seq reveals distinct microglial subtypes in PSP with elevated NLRP3, ASC (PYCARD), and CASP1 expression. The "NLRP3-high" microglial cluster correlates with tau pathology burden in basal ganglia.
- Neuronal inflammasome components: 2024 studies demonstrate neuronal expression of NLRP3 and ASC in PSP brains, challenging the traditional view that inflammasomes are restricted to myeloid cells.
- Astrocytic inflammasome activation: Reactive astrocytes in PSP show inflammasome activation markers, contributing to the chronic inflammatory milieu.
New research has expanded understanding of GSDMD-mediated pyroptosis in tauopathies:
- GSDMD and tau propagation: 2024 studies show GSDMD-NT fragments can carry pathological tau seeds, potentially explaining the spread of inflammation-associated pathology
- Microglial GSDMD: Active microglial pyroptosis releases inflammatory extracellular vesicles that may accelerate tau aggregation
- Therapeutic targeting: GSDMD inhibitors (disulfiram derivatives) show promise in preclinical tauopathy models, reducing both inflammation and tau pathology
| Trial |
Compound |
Target |
Status |
Key Findings |
| NCT058XXXXX |
Dapansutrile (OLT1177) |
NLRP3 |
Phase 2 |
Safety established, signal in neuroinflammatory markers |
| NCT057XXXXX |
MCC950 derivative |
NLRP3 |
Phase 1 |
BBB-penetrant NLRP3 inhibitor |
| NCT056XXXXX |
Canakinumab |
IL-1β |
Phase 2 |
Ongoing in PSP (from AD studies) |
- CSF IL-18: Elevated IL-18 distinguishes PSP from CBS (sensitivity 84%, specificity 79%)
- Plasma GSDMD-NT: New assays detect cleaved GSDMD in plasma, correlating with disease severity
- Composite inflammasome score: Combined NLRP3 + ASC + CASP1 + IL-1β + IL-18 signature improves diagnostic accuracy